Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU CSP Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU creativebharatgroup@gmail.com December 10, 2024 Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet... Read More Read more about Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
